Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 6/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261313 | 0.76 | HIF1A (0.57) | HIF1A | |
| SCHEMBL30089488 | 0.73 | SLC5A2 (0.49) | HIF1AADAPYGLSLC5A2 | |
| SCHEMBL30494660 | 0.73 | SLC5A2 (0.49) | HIF1AADAPYGLSLC5A2 | |
| SCHEMBL11150682 | 0.73 | SLC5A2 (0.49) | HIF1AADAPYGLSLC5A2 | |
| SCHEMBL28147525 | 0.70 | HIF1A (0.45) | HIF1AADAPYGLSLC5A2 | |
| Deaminoformycin SCHEMBL5071997 | 0.69 | HIF1A (0.46) | HIF1AADAPYGL | |
| Deaminoformycin SCHEMBL11670040 | 0.69 | ADA (0.45) | HIF1AADAPYGL | |
| Deaminoformycin SCHEMBL14217783 | 0.69 | HIF1A (0.46) | HIF1AADAPYGL | |
| SCHEMBL30025957 | 0.69 | SLC5A2 (0.45) | HIF1AADAPYGLSLC5A2 | |
| SCHEMBL1594082 | 0.69 | SLC5A2 (0.45) | HIF1AADAPYGLSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2396340-B1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2396340-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | HIF1A 3588/4885ADA 14/4885PYGL 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.